Press release content from Accesswire. The AP news staff was not involved in its creation.
Core One Labs to Rescind Share Exchange with Plant-Based Investment Corp.
April 15, 2021 GMT
VANCOUVER, BC / ACCESSWIRE / April 14, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FRA:LD62)(WKN:A2P8K3) (the Company or Core One ) announces that it has reached an agreement with Plant-Based Investment Corp. (formerly, Cannabis Growth .
VANCOUVER, BC / ACCESSWIRE / April 14, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FRA:LD62)(WKN:A2P8K3) (the Company or Core One ) announces that it has reached an agreement with Plant-Based Investment Corp. (formerly, Cannabis Growth .
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
InspireMD Announces 1-for-15 Reverse Stock Split
InspireMD Inc.April 14, 2021 GMT
TEL AVIV, Israel, April 14, 2021 (GLOBE NEWSWIRE) InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced a 1-for-15 reverse split of its common stock, effective as of April 26, 2021. Beginning on April 27, 2021, the Company’s common stock will trade on the NYSE American on a split adjusted basis.
At InspireMD’s special meeting of stockholders on April 14, 2021, the Company’s stockholders authorized the Board of Directors to amend the Amended and Restated Certificate of Incorporation of the Company to effect a reverse stock split at a ratio in the range of 1-for-10 to 1-for-20.
Press release content from Business Wire. The AP news staff was not involved in its creation.
ROSALIND, HELiXrUS and Geninus Partner to Bring Powerful New Single Cell Analysis Services to Cancer Researchers
April 15, 2021 GMT
SAN DIEGO & SEOUL, South Korea (BUSINESS WIRE) Apr 15, 2021
ROSALIND ®, a software leader in extracting meaningful insights from diverse pools of life science data, today announced that it has partnered with two Seoul-based technology providers to enable a powerful new Single Cell data analysis solution for cancer research scientists in Asia. Geninus, a leading full-service genomics laboratory, will combine the ROSALIND platform with its Celinus™ single cell RNA sequencing service to enable expanded analysis and interpretation of data, as well as seamless sharing and collaboration across labs and geographies. HELiXrUS, a channel partnership company focused on biological big data and multi-omics, played a leading role in establishing this partnership and
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CytoDyn Executes Exclusive Supply and Distribution Agreement with Chiral Pharma Corporation to .
CytoDyn Inc.April 15, 2021 GMT
Under Compassionate Special Permit (CSP) in Philippines, CytoDyn is well positioned to generate significant revenues
VANCOUVER, Washington., April 15, 2021 (GLOBE NEWSWIRE) CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today it has executed an exclusive supply and distribution agreement with Chiral Pharma Corporation to supply up to 200,000 vials of leronlimab to critically ill COVID-19 patients in the Philippines under CSP authorizations. This agreement will accelerate the delivery of leronlimab upon an expanded authorization under CSP.